Computational models of HIV-1 resistance to gene therapy elucidate therapy design principles

PLoS Computational Biology

Volumn 6, Issue 8, 2010, Pages

  Aviran, Sharon ^a   Shah, Priya S ^b   Schaffer, David V ^a,b,c   Arkin, Adam P ^a,d  

^a University of California at Berkeley   (United States)

^b University of California   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTONOMOUS AGENTS; CELL CULTURE; CELL PROLIFERATION; COMPUTATION THEORY; COMPUTATIONAL METHODS; DYNAMICS; GENE TRANSFER; LIFE CYCLE; VIRUSES;

'CURRENT; ANTI-HIV; COMPUTATIONAL MODELLING; CRITICAL CHALLENGES; DESIGN PRINCIPLES; EVOLUTIONARY DYNAMICS; GENETICALLY MODIFIED; IN-VIVO; PROPERTY; THERAPY DESIGN;

GENE THERAPY;

ANTIRETROVIRUS AGENT; COMPLEMENTARY RNA;

ARTICLE; CELL POPULATION; CELL PROLIFERATION; CLINICAL TRIAL; DNA MODIFICATION; EX VIVO GENE TRANSFER; GENE TARGETING; GENE TECHNOLOGY; GENE THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIFE CYCLE; LONG TERM CARE; MATHEMATICAL MODEL; NONHUMAN; SHORT COURSE THERAPY; VIRAL GENE THERAPY; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78049429450     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1000883     Document Type: Article

References (90)

1. Johnston MI, Fauci AS (2008) An HIV Vaccine- Challenges and Prospects. N Engl J Med 359: 888-890.
2. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, et al. (2009) The Challenge of Finding a Cure for HIV Infection. Science 323: 1304-1307.
3. Clavel F, Hance AJ (2004) HIV Drug Resistance. N Engl J Med 350: 1023-1035.
4. Rossi JJ, June CH, Kohn DB (2007) Genetic therapies against HIV. Nat Biotechnol 25: 1444-1454.
5. Levine BL, Humeau LM, Boyer J, MacGregor R-R, Rebello T, et al. (2006) Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 103: 17372-17377.
6. van Lunzen J, Glaunsinger T, Stahmer I, Baehr Vv, Baum C, et al. (2007) Transfer of Autologous Gene-modified T Cells in HIV-infected Patients with Advanced Immunodeficiency and Drug-resistant Virus. Mol Ther 15: 1024-1033.
7. Morgan RA, Walker R, Carter CS, Natarajan V, Tavel JA, et al. (2005) Preferential Survival of CD4+ T Lymphocytes Engineered with Anti-Human Immunodeficiency Virus (HIV) Genes in HIV-Infected Individuals. Hum Gene Ther 16: 1065-1074.
8. Swan CH, Torbett BE (2006) Can gene delivery close the door to HIV-1 entry after escape? J Med Primatol 35: 236-247.
9. Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, et al. (2004) Human Immunodeficiency Virus Type 1 Escapes from RNA Interference- Mediated Inhibition. J Virol 78: 2601-2605.
10. Hermann FG, Egerer L, Brauer F, Gerum C, Schwalbe H, et al. (2009) Mutations in gp120 Contribute to the Resistance of Human Immunodeficiency Virus Type 1 to Membrane-Anchored C-Peptide maC46. J Virol 83: 4844-4853.
11. Lu X, Yu Q, Binder GK, Chen Z, Slepushkina T, et al. (2004) Antisense- Mediated Inhibition of Human Immunodeficiency Virus (HIV) Replication by Use of an HIV Type 1-Based Vector Results in Severely Attenuated Mutants Incapable of Developing Resistance. J Virol 78: 7079-7088.
12. ter Brake O, Konstantinova P, Ceylan M, Berkhout B (2006) Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther 14: 883-892.
13. Li M-J, Kim J, Li S, Zaia J, Yee J-K, et al. (2005) Long-Term Inhibition of HIV- 1 Infection in Primary Hematopoietic Cells by Lentiviral Vector Delivery of a Triple Combination of Anti-HIV shRNA, Anti-CCR5 Ribozyme, and a Nucleolar-Localizing TAR Decoy. Mol Ther 12: 900-909.
14. Scherer L, Rossi JJ, Weinberg MS (2007) Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther 14: 1057-1064.
15. Nowak MA (2006) Evolutionary dynamics: exploring the equations of life. Cambridge Mass.: Harvard University Press.
16. Nowak MA, May RM (2000) Virus dynamics: mathematical principles of immunology and virology. Oxford, England: Oxford University Press.
17. Perelson AS (2002) Modelling viral and immune system dynamics. Nat Rev Immun 2: 28-36.
18. Rouzine IM, Rodrigo A, Coffin JM (2001) Transition between stochastic evolution and deterministic evolution in the presence of selection: general theory and application to virology. Microbiol Mol Biol Rev 65: 151-185.
19. Lund O, Lund O, Gram G, Nielsen S, Schanning K, et al. (1997) Gene therapy of T helper cells in HIV infection: Mathematical model of the criteria for clinical effect. Bull Math Biol 59: 725-745.
20. Weinberger LS, Schaffer DV, Arkin AP (2003) Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. J Virol 77: 10028-10036.
21. von Laer D, Hasselmann S, Hasselmann K (2006) Impact of gene-modified T cells on HIV infection dynamics. J Theor Biol 238: 60-77.
22. Leonard JN, Schaffer DV (2005) Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape. J Virol 79: 1645-1654.
23. Leonard JN, Shah PS, Burnett JC, Schaffer DV (2008) HIV evades RNA interference directed at TAR by an indirect compensatory mechanism. Cell Host Microbe 4: 484-494.
24. Dropulic B, June CH (2006) Gene-Based Immunotherapy for Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. Hum Gene Ther 17: 577-588.
25. von Laer D, Baum C, Protzer U (2009) Antiviral Gene Therapy Antiviral Strategies. pp 265-297.
26. Johnson JA, Li J-F, Wei X, Lipscomb J, Irlbeck D, et al. (2008) Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment-Naive Populations and Associate with Reduced Treatment Efficacy. PLoS Med 5: e158.
27. Lapadula G, Izzo I, Gargiulo F, Paraninfo G, Castelnuovo F, et al. (2008) Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: a single center analysis. J Med Virol 80: 747-753.
28. An DS, Donahue RE, Kamata M, Poon B, Metzger M, et al. (2007) Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in nonhuman primates. Proc Natl Acad Sci U S A 104: 13110-13115.
29. Anderson J, Akkina R (2005) CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection. Retrovirology 2: 53.
30. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, et al. (2008) Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26: 808-816.
31. Swan CH, Buhler B, Tschan MP, Barbas CF, III, Torbett BE (2006) T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther 13: 1480-1492.
32. Masiero S, Del Vecchio C, Gavioli R, Mattiuzzo G, Cusi MG, et al. (2004) Tcell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther 12: 299-310.
33. Li Y, Li X, Stremlau M, Lee M, Sodroski J (2006) Removal of Arginine 332 Allows Human TRIM5a To Bind Human Immunodeficiency Virus Capsids and To Restrict Infection. J Virol 80: 6738-6744.
34. June CH, Blazar BR, Riley JL (2009) Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 9: 704-716.
35. Paulos C, Suhoski M, Plesa G, Jiang T, Basu S, et al. (2008) Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol Res 42: 182-196.
36. DiGiusto DL, Krishnan A, Li L, Li H, Li S, et al. (2010) Safety and feasibility of lentiviral vector-modified CD34+ cells in the setting of autologous transplantation for AIDS-related lymphoma. Sci Transl Med 2: 36ra43.
37. De Boer RJ, Perelson AS (1995) Towards a general function describing t cell proliferation. J Theor Biol 175: 567-576.
38. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
39. Rong L, Perelson AS (2009) Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol 260: 308-331.
40. Simon V, Ho DD (2003) HIV-1 dynamics in vivo: implications for therapy. Nat Rev Microbiol 1: 181-190.
41. Kiem H-P, Wu RA, Sun G, von Laer D, Rossi JJ, et al. (2010) Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo. Gene Ther 17: 37-49.
42. von Laer D, Hasselmann S, Hasselmann K (2006) Gene therapy for HIV infection: what does it need to make it work? J Gene Med 8: 658-667.
43. Egelhofer M, Brandenburg G, Martinius H, Schult-Dietrich P, Melikyan G, et al. (2004) Inhibition of Human Immunodeficiency Virus Type 1 Entry in Cells Expressing gp41-Derived Peptides. J Virol 78: 568-575.
44. Hermann FG, Martinius H, Egelhofer M, Giroglou T, Tonn T, et al. (2009) Protein Scaffold and Expression Level Determine Antiviral Activity of Membrane-Anchored Antiviral Peptides. Hum Gene Ther 20: 325-336.
45. Murray JM, Kaufmann GR, Hodgkin PD, Lewin SR, Kelleher AD, et al. (2003) Naive T cells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty. Immunol Cell Biol 81: 487-495.
46. Lamar DL, Weyand CM, Goronzy JJ (2009) Age, T-cell Homeostasis, and T-cell Diversity in Humans Handbook on Immunosenescence. pp 167-192.
47. Douek DC, Betts MR, Hill BJ, Little SJ, Lempicki R, et al. (2001) Evidence for Increased T Cell Turnover and Decreased Thymic Output in HIV Infection. J Immunol 167: 6663-6668.
48. Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, et al. (1995) Age, Thymopoiesis, and CD4+ T-Lymphocyte Regeneration after Intensive Chemotherapy. N Engl J Med 332: 143-149.
49. Pena Mdl, Elena SF, Moya A (2000) Effect of Deleterious Mutation- Accumulation on the Fitness of RNA Bacteriophage MS2. Evolution 54: 686-691.
50. Montville R, Froissart R, Remold SK, Tenaillon O, Turner PE (2005) Evolution of Mutational Robustness in an RNA Virus. PLoS Biol 3: e381.
51. Krakauer DC, Plotkin JB (2002) Redundancy, antiredundancy, and the robustness of genomes. Proc Natl Acad Sci U S A 99: 1405-1409.
52. Collins JA, Thompson MG, Paintsil E, Ricketts M, Gedzior J, et al. (2004) Competitive Fitness of Nevirapine-Resistant Human Immunodeficiency Virus Type 1 Mutants. J Virol 78: 603-611.
53. Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ (2004) Evidence for Positive Epistasis in HIV-1. Science 306: 1547-1550.
54. Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley MG (2005) Selection and characterization of HIV-1 showing reduced susceptibility to the nonpeptidic protease inhibitor tipranavir. Antiviral Res 68: 27-35.
55. Goudsmit J, de Ronde A, de Rooij E, de Boer R (1997) Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J Virol 71: 4479-4484.
56. Maree AFM, Keulen W, Boucher CAB, De Boer RJ (2000) Estimating relative fitness in viral competition experiments. J Virol 74: 11067-11072.
57. Wu H, Huang Y, Dykes C, Liu D, Ma J, et al. (2006) Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay. J Virol 80: 2380-2389.
58. Dykes C, Demeter LM (2007) Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness. Clin Microbiol Rev 20: 550-578.
59. Wiethoff CM, Middaugh CR (2003) Barriers to nonviral gene delivery. J Pharm Sci 92: 203-217.
60. Leonard JN, Schaffer DV (2005) Antiviral RNAi therapy: emerging approaches for hitting a moving target. Gene Ther 13: 532-540.
61. An DS, Qin FX-F, Auyeung VC, Mao SH, Kung SKP, et al. (2006) Optimization and Functional Effects of Stable Short Hairpin RNA Expression in Primary Human Lymphocytes via Lentiviral Vectors. Mol Ther 14: 494-504.
62. Rowley J, Monie A, Hung C-F, Wu T-C (2009) Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis. Eur J Immunol 39: 491-506.
63. Chen C-Z, Li L, Lodish HF, Bartel DP (2004) MicroRNAs Modulate Hematopoietic Lineage Differentiation. Science 303: 83-86.
64. Dagarag M, Evazyan T, Rao N, Effros RB (2004) Genetic Manipulation of Telomerase in HIV-Specific CD8+ T Cells: Enhanced Antiviral Functions Accompany the Increased Proliferative Potential and Telomere Length Stabilization. J Immunol 173: 6303-6311.
65. Hsu C, Hughes MS, Zheng Z, Bray RB, Rosenberg SA, et al. (2005) Primary Human T Lymphocytes Engineered with a Codon-Optimized IL-15 Gene Resist Cytokine Withdrawal-Induced Apoptosis and Persist Long-Term in the Absence of Exogenous Cytokine. J Immunol 175: 7226-7234.
66. Roth A, Baerlocher GM, Schertzer M, Chavez E, Duhrsen U, et al. (2005) Telomere loss, senescence, and genetic instability in CD4+ T lymphocytes overexpressing hTERT. Blood 106: 43-50.
67. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, et al. (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541.
68. Castanotto D, Sakurai K, Lingeman R, Li H, Shively L, et al. (2007) Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucl Acids Res 35: 5154-5164.
69. McCune JM, Hanley MB, Cesar D, Halvorsen R, Hoh R, et al. (2000) Factors influencing T-cell turnover in HIV-1-seropositive patients. J Clin Invest 105: R1-R8.
70. Ribeiro RM, Mohri H, Ho DD, Perelson AS (2002) In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: Why are CD4+ but not CD8+ T cells depleted? Proc Natl Acad Sci U S A 99: 15572-15577.
71. Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, et al. (2009) Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 15: 285-292.
72. Neff T, Beard BC, Kiem H-P (2006) Survival of the fittest: in vivo selection and stem cell gene therapy. Blood 107: 1751-1760.
73. Maier P, Spier I, Laufs S, Veldwijk MR, Fruehauf S, et al. (2010) Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O6-methylguanine-DNA methyltransferaseP140K. Gene Ther 17: 389-399.
74. Trobridge GD, Wu RA, Beard BC, Chiu SY, Muñz NM, et al. (2009) Protection of Stem Cell-Derived Lymphocytes in a Primate AIDS Gene Therapy Model after In Vivo Selection. PLoS One 4: e7693.
75. Cohen J (2007) Building an HIV-Proof Immune System. Science 317: 612-614.
76. Bretscher MT, Althaus CL, Müller V, Bonhoeffer S (2004) Recombination in HIV and the evolution of drug resistance: for better or for worse? Bioessays 26: 180-188.
77. Arora P, Dixit NM (2009) Timing the emergence of resistance to anti-HIV drugs with large genetic barriers. PLoS Comput Biol 5: e1000305.
78. Trobridge G, Beard BC, Kiem H-P (2005) Hematopoietic Stem Cell Transduction and Amplification in Large Animal Models. Hum Gene Ther 16: 1355-1366.
79. Berzins SP, Uldrich AP, Sutherland JS, Gill J, Miller JFAP, et al. (2002) Thymic regeneration: teaching an old immune system new tricks. Trends Mol Med 8: 469-476.
80. Jameson SC (2002) Maintaining the norm: T-cell homeostasis. Nat Rev Immunol 2: 547-556.
81. Thomas-Vaslin V, Altes HK, de Boer RJ, Klatzmann D (2008) Comprehensive Assessment and Mathematical Modeling of T Cell Population Dynamics and Homeostasis. J Immunol 180: 2240-2250.
82. Vallanti G, Lupo R, Federico M, Mavilio F, Bovolenta C (2005) T Lymphocytes Transduced with a Lentiviral Vector Expressing F12-vif Are Protected from HIV-1 Infection in an APOBEC3G-Independent Manner. Mol Ther 12: 697-706.
83. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.
84. Perelson AS, Essunger P, Cao YZ, Vesanen M, Hurley A, et al. (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387: 188-191.
85. Ribeiro RM, Bonhoeffer S (2000) Production of resistant HIV mutants during antiretroviral therapy. Proc Natl Acad Sci U S A 97: 7681-7686.
86. Curlin ME, Iyer S, Mittler JE (2007) Optimal timing and duration of induction therapy for HIV-1 infection. PLoS Comput Biol 3: 1239-1256.
87. Baxter JD, Schapiro JM, Boucher CAB, Kohlbrenner VM, Hall DB, et al. (2006) Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir. J Virol 80: 10794-10801.
88. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, et al. (1999) Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 354: 1782-1785.
89. Mansky L, Temin H (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69: 5087-5094.
90. Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, et al. (1999) Directly measured kinetics of circulating T lymphocytes in normal and HIV-1- infected humans. Nat Med 5: 83-89.